Please login to the form below
Synagis
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Synagis was produced by AstraZeneca and AbbVie.
Sobi shows strong growth despite haemophilia competition
November also saw Sobi acquire rights to Synagis, the only approved respiratory syncytial virus (RSV) prophylaxis for high-risk infants from AstraZeneca. ... We completed the acquisition of Synagis in late January and are in the process of integrating
US, EU regulators back rapid reviews of AZ’s RSV med
MEDI8897 is a longer-acting follow-up to AZ’s Synagis (palivizumab), which is currently the only drug approved for preventing RSV in high-risk patients. ... Synagis has been a nice earner for AZ, making almost $700m in revenues in 2017, but has started
FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease
Earlier this month, Sobi agreed to acquire the US rights to AstraZeneca’s respiratory syncytial virus (RSV) prevention drug Synagis (palivizumab) in a deal worth $1.5bn. ... Sobi's Guido Oelkers. “Gamifant will add significant strength to Sobi’s
AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi
s focus on Synagis will enable infants in the US to continue benefiting from this important treatment.”. ... The addition of Synagis will become an important strategic catalyst for Sobi’s future development and will form a powerful platform for
Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi
AZ sells a prophylactic RSV antibody - Synagis (palivizumab) - which brought in $677m in sales in 2016 despite being reserved for use in high-risk infants.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Imperial College London to lead major coronavirus home testing programme
- ViiV takes on Gilead’s PReP dominance with HIV injectable data
- Moderna’s coronavirus vaccine hits first objectives
- Roche says antibody test for COVID-19 should be ready in May
- AZ secures capacity for one billion coronavirus vaccine doses
- UK’s new COVID-19 trial initiative fast-tracks BerGenBio’s bemcentinib
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
- Gilead, Galapagos dip on mixed ulcerative colitis data
- Roche makes protein degradation play with $135m Vividion deal
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- UK government expands coronavirus testing criteria
PMHub
EPG Health
REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...
Latest intelligence
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
- OPEN Health use PR to support clinical trial recruitment
- International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
- Covid-19: what could it mean for the diabetic population?
- Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...
Quick links
Infographics
